Enanta Pharmaceuticals Long Term Debt

Enanta Pharmaceuticals (ENTA) currently reports a long-term debt of $150M as of March 2026. That compares with $57M in the prior-year period — up 167.8% year over year. Use the charts on this page to explore Enanta Pharmaceuticals's long-term debt history and peer comparisons.

Enanta Pharmaceuticals's long-term debt increased from $57M to $150M — a 167.8% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Enanta Pharmaceuticals reported $150M in long-term debt as of March 2026. That compares with $57M in the prior-year period — up 167.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $150M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Enanta Pharmaceuticals, and consider following ENTA for alerts when major investors trade the stock.

Enanta Pharmaceuticals is classified in the Healthcare sector. On long-term debt, it currently shows $150M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ENTA with unrelated industries.